Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709957 | 0.89 | HPGD (0.33) | POLBHPGDCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3026394 | 0.86 | POLB (0.36) | ABCB1POLBMAPK1 | |
| SCHEMBL718787 | 0.84 | POLB (0.31) | POLBMAPK1 | |
| SCHEMBL3024748 | 0.84 | POLB (0.34) | ABCB1POLBMAPK1 | |
| SCHEMBL3029793 | 0.81 | POLB (0.32) | POLBMAPK1 | |
| SCHEMBL709355 | 0.81 | HPGD (0.37) | POLBHPGDCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3019892 | 0.78 | POLB (0.31) | POLBMAPK1 | |
| SCHEMBL711738 | 0.77 | POLB (0.35) | ABCB1POLBMAPK1HPGDLMNA | |
| SCHEMBL3024604 | 0.76 | POLB (0.31) | POLBMAPK1 | |
| SCHEMBL3030375 | 0.73 | LMNA (0.35) | POLBMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| EP-1989179-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-26 | — | — | EP | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| EP-1989179-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2008-11-12 | — | — | EP | disclosed |
| US-20080260651-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2008-10-23 | — | — | US | disclosed |
| WO-2007094683-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053142-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | ABCB1 1668/4885POLB 2876/4885MAPK1 1809/4885 |
| US-20080260651-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | ABCB1 2127/4885POLB 1993/4885MAPK1 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.